Cerivastatin Induces Rhabdomyolysis and Acute Renal Failure

Paolo, N. Di; Monaci, Giulio; Cappelletti, Francesca; Paolo, Marco Di; Verzuri, Maria Serena

doi:10.1159/000064102

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased risk of rhabdomyolysis associated with cerivastatin was not identified in premarketing clinical trials, but became apparent on post‐marketing surveillance (8, 9). Clinical features of our case coincided with typical rhabdomyolysis.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis

Ozaki¹,

Ishikawa²,

Ishii³

et al. 2005

J Clin Pharm Ther

View full text Add to dashboard Cite

We report on a patient who developed acute rhabdomyolysis after taking cerivastatin. A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain. Her serum creatinine phosphokinase level was 19,190 IU/L. Serum myoglobin was over 3000 ng/mL. Serum concentration of cerivastatin at 6 h after taking the last dose (0.15 mg) was 8062.5 ng/L, which was almost 5.7 times higher than that of normal persons. The serum concentration of cerivastatin showed that the half-life of cerivastatin in this patient was 22.4 h, compared with 2.4 h for normal controls. Cerivastatin is catabolized by cytochrome P450, 3A4 and 2C8 to M-1, and by 2C8 to M-23. The ratio of M-23 to M-1 in her serum was much lower than that of control persons (0.64 vs. 2.08). She had previously taken simvastatin which is metabolized by CYP3A4, without any sign and symptoms of rhabdomyolysis. These results suggest that the slowed clearance of cerivastatin in this patient might have been compounded by cytochrome P450, 2C8 dysfunction.

show abstract

Section: Resultsmentioning

confidence: 99%

“…However, adverse reactions involving skeletal muscles range from mild myopathy to rhabdomyolysis (6, 7). Rhabdomyolysis with cerivastatin administration have been reported from all over the world (8, 9). Generally, rhabdomyolysis seems to occur with large doses of statins.…”

Section: Introductionmentioning

confidence: 99%

Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis

Ozaki¹,

Ishikawa²,

Ishii³

et al. 2005

J Clin Pharm Ther

View full text Add to dashboard Cite

show abstract

Current Awareness: Pharmacoepidemiology and Drug Safety

2003

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract